Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Circulating Tumor DNA in High-Risk Stage II/III Cutaneous Melanoma: A Feasibility Study.

A single-institution prospective study tested the feasibility of serial Signatera ctDNA monitoring in clinical stage IIB, IIC, and III melanoma.

Annals of Surgical OncologyPubMed 40146490DOI 10.1245/s10434-025-17194-z